Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Qiu Min
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Beta
- 0.42
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -41.22
Financials
Revenue
$0.00-100.0%Net Income
$-849.0KEBITDA
$-1.63MFree Cash Flow
$-3.83MEPS (diluted)
$-0.02Shares Outstanding (diluted)
41.12M+143.6%Operating Expenses
$1.73MCash & Debt
$6.53MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-7.99M | $-0.20 |
| 2024 | $0.00 | $-11.12M | $-0.28 |
| 2023 | $0.00 | $-21.03M | $-0.54 |
| 2022 | $1.35M | $-33.28M | $-0.85 |
| 2021 | $1.35M | $-64.18M | $-1.64 |
| 2020 | $180.0K | $-60.97M | $-2.04 |
| 2019 | $0.00 | $-38.09M | $-1.55 |
| 2018 | $0.00 | $-54.87M | $-2.42 |
| 2017 | $0.00 | $-91.76M | $-4.40 |
| 2016 | $0.00 | $-12.01M | $-0.75 |
| 2015 | $0.00 | $-7.97M | $-0.53 |
| 2014 | $0.00 | $-3.01M | $-0.19 |
Valuation
BYSIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
140+133.33%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·6d ago·Positive
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript
View source ↗ - Newsglobenewswire.com·7d ago·Negative
…ransaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment of cancer and other diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or metastatic …
View source ↗ - Newsglobenewswire.com·52d ago·Positive
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.54 per share
Typical surprise +90.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.02 vs $-0.54beat
- Wed, May 13$-0.05 vs $-0.54beat
- Wed, Mar 25$-0.05 vs $-0.54beat
Estimates and results for BYSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BYSI officers and directors.
- Bought
- —
- Sold
- $2.0m
0 trades
63 trades
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
- Decheng Capital China Life Sciences Usd Fund Iii, L.p.sold
37 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BYSI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.